EU/3/10/799: Orphan designation for the treatment of cowpox infection



On 1 October 2010, orphan designation (EU/3/10/799) was granted by the European Commission to SIGA Pharmaceuticals (Europe) Ltd, United Kingdom, for tecovirimat (also known as ST-246) for the treatment of cowpox infection.

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2012 on request of the sponsor.

Key facts

Active substance
Intended use
Treatment of cowpox infection
Orphan designation status
EU designation number
Date of designation
SIGA Pharmaceuticals (Europe) Ltd
c/o Jordans Limited
20-22 Bedford Row
London WC1R 4JS
United Kingdom
Telephone: +1 951 303 8797
Telefax: +1 541 753 9999

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating